» Articles » PMID: 38675104

Brain Organoids: A Game-Changer for Drug Testing

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2024 Apr 27
PMID 38675104
Authors
Affiliations
Soon will be listed here.
Abstract

Neurological disorders are the second cause of death and the leading cause of disability worldwide. Unfortunately, no cure exists for these disorders, but the actual therapies are only able to ameliorate people's quality of life. Thus, there is an urgent need to test potential therapeutic approaches. Brain organoids are a possible valuable tool in the study of the brain, due to their ability to reproduce different brain regions and maturation stages; they can be used also as a tool for disease modelling and target identification of neurological disorders. Recently, brain organoids have been used in drug-screening processes, even if there are several limitations to overcome. This review focuses on the description of brain organoid development and drug-screening processes, discussing the advantages, challenges, and limitations of the use of organoids in modeling neurological diseases. We also highlighted the potential of testing novel therapeutic approaches. Finally, we examine the challenges and future directions to improve the drug-screening process.

Citing Articles

Harnessing the potential of human induced pluripotent stem cells, functional assays and machine learning for neurodevelopmental disorders.

Yang Z, Teaney N, Buttermore E, Sahin M, Afshar-Saber W Front Neurosci. 2025; 18:1524577.

PMID: 39844857 PMC: 11750789. DOI: 10.3389/fnins.2024.1524577.


Limitations of human brain organoids to study neurodegenerative diseases: a manual to survive.

Urrestizala-Arenaza N, Cerchio S, Cavaliere F, Magliaro C Front Cell Neurosci. 2024; 18:1419526.

PMID: 39049825 PMC: 11267621. DOI: 10.3389/fncel.2024.1419526.


: A Leaf of Hope in the Fight against Alzheimer's Dementia: Clinical Trial Systematic Review.

Pagotto G, Santos L, Osman N, Lamas C, Fornari Laurindo L, Pomini K Antioxidants (Basel). 2024; 13(6).

PMID: 38929090 PMC: 11201198. DOI: 10.3390/antiox13060651.


Guidelines for Manufacturing and Application of Organoids: Brain.

Kwak T, Park S, Lee S, Shin Y, Yoon K, Cho S Int J Stem Cells. 2024; 17(2):158-181.

PMID: 38777830 PMC: 11170118. DOI: 10.15283/ijsc24056.

References
1.
Nestor M, Paull D, Jacob S, Sproul A, Alsaffar A, Campos B . Differentiation of serum-free embryoid bodies from human induced pluripotent stem cells into networks. Stem Cell Res. 2013; 10(3):454-63. DOI: 10.1016/j.scr.2013.02.001. View

2.
Wakimoto H, Kesari S, Farrell C, Curry Jr W, Zaupa C, Aghi M . Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 2009; 69(8):3472-81. PMC: 2785462. DOI: 10.1158/0008-5472.CAN-08-3886. View

3.
Heydari Z, Moeinvaziri F, Agarwal T, Pooyan P, Shpichka A, Maiti T . Organoids: a novel modality in disease modeling. Biodes Manuf. 2021; 4(4):689-716. PMC: 8349706. DOI: 10.1007/s42242-021-00150-7. View

4.
Zerr I, Parchi P . Sporadic Creutzfeldt-Jakob disease. Handb Clin Neurol. 2018; 153:155-174. DOI: 10.1016/B978-0-444-63945-5.00009-X. View

5.
Durens M, Nestor J, Williams M, Herold K, Niescier R, Lunden J . High-throughput screening of human induced pluripotent stem cell-derived brain organoids. J Neurosci Methods. 2020; 335:108627. DOI: 10.1016/j.jneumeth.2020.108627. View